These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 25864171)
1. Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions. Chang JH; Lim Joon D; Davis ID; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Bolton D; Scott AM; Khoo V Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):438-45. PubMed ID: 25864171 [TBL] [Abstract][Full Text] [Related]
2. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686 [TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Chang JH; Lim Joon D; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Tochon-Danguy H; Chan JG; Bolton D; Scott AM; Khoo V; Davis ID Eur Radiol; 2014 Mar; 24(3):715-22. PubMed ID: 24192979 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions. Scobioala S; Kittel C; Wolters H; Huss S; Elsayad K; Seifert R; Stegger L; Weckesser M; Haverkamp U; Eich HT; Rahbar K Ann Nucl Med; 2021 May; 35(5):628-638. PubMed ID: 33742373 [TBL] [Abstract][Full Text] [Related]
5. Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Chang JH; Joon DL; Lee ST; Gong SJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V Radiother Oncol; 2011 May; 99(2):187-92. PubMed ID: 21600669 [TBL] [Abstract][Full Text] [Related]
6. Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation? Van den Bergh L; Isebaert S; Koole M; Oyen R; Joniau S; Lerut E; Deroose CM; De Keyzer F; Van Poppel H; Haustermans K Strahlenther Onkol; 2013 Sep; 189(9):789-95. PubMed ID: 23797481 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer GTV delineation with biparametric MRI and Hearn N; Blazak J; Vivian P; Vignarajah D; Cahill K; Atwell D; Lagopoulos J; Min M Br J Radiol; 2021 Mar; 94(1119):20201174. PubMed ID: 33507812 [TBL] [Abstract][Full Text] [Related]
8. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma. Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847 [TBL] [Abstract][Full Text] [Related]
9. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans. Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190 [TBL] [Abstract][Full Text] [Related]
11. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography. Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904 [TBL] [Abstract][Full Text] [Related]
13. Metabolic Volumetric Parameters in Tseng JR; Yang LY; Lin YC; Liu CY; Pang ST; Hong JH; Yen TC; Wang LJ Contrast Media Mol Imaging; 2018; 2018():8945130. PubMed ID: 30532664 [TBL] [Abstract][Full Text] [Related]
14. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082 [TBL] [Abstract][Full Text] [Related]